IDEXX LABORATORIES INC /DE — Director's Dealing 2021

Jun 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-05-28

Reporting Person: AYERS JONATHAN W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-12	Common Stock	G	9000	—	Disposed	644701	Direct
2021-05-28	Common Stock	M	9460	$79.54	Acquired	654161	Direct
2021-05-28	Common Stock	S	2482	$560.3772	Disposed	651679	Direct
2021-05-28	Common Stock	S	1664	$561.5728	Disposed	650015	Direct
2021-05-28	Common Stock	S	2599	$562.4772	Disposed	647416	Direct
2021-05-28	Common Stock	S	1400	$563.8159	Disposed	646016	Direct
2021-05-28	Common Stock	S	1315	$564.6044	Disposed	644701	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-28	Non-Qualified Stock Option (right-to-buy)	$79.54	M	9460	Disposed	2025-02-13	Common Stock (9460)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect

Footnotes

F1: Represents the weighted average price of the shares sold ranging from a low of $560.00 to a high of $561.00 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average price of the shares sold ranging from a low of $561.005 to a high of $561.92 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $562.02 to a high of $563.02 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $563.03 to a high of $564.03 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Represents the weighted average price of the shares sold ranging from a low of $564.11 to a high of $564.93 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F6: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Not applicable.